The US’s policy under the Second Donald Trump Administration has undergone major changes, with experts saying that America is ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

After reporting in April that its gastrointestinal reprogramming product (Garp) failed to meet the primary efficacy endpoint in a phase II trial in irritable bowel syndrome (IBS), Anatara Lifesciences ...

Pfizer is licensing a promising investigational cancer medicine from a smaller company. This move improves the drugmaker's ...

Pfizer has struck a massive $1.25 billion deal with China’s 3SBio to license a promising cancer drug, beefing up its oncology ...